A Phase 2 interventional study of PP405 0.05% Topical Gel and Topical Vehicle Gel in Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Pelage Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 216 studies in Alopecia with a site in United States, this one is the 55th largest by enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2024, is one of 47 in phase 2, and was the 172nd registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
K. Kay Durairaj, MD, FACS, A Medical Corporation · Sites in United States
Ages 35–55 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 57 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 203 interventional studies, 204 across the 12 observational. Of the 126 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
123 of 216 have an industry lead sponsor. The 10 most frequent:
Pelage Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Pelage Pharmaceuticals, Inc. has 3 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 216 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.
Safety, Pharmacokinetics, and Efficacy Study of PP405 in subjects with Androgenetic Alopecia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PP405 0.05% Topical Gel applied once daily for 28 days.
Drug: PP405 0.05% Topical Gel
Topical Placebo Gel applied once daily for 28 days. Following the initial treatment and follow-up period through day 84, eligible subjects crossed over to apply PP405 0.05% topical gel for 84 days in an open-labeled extension.
Drug: PP405 0.05% Topical Gel · Drug: Topical Vehicle Gel
Medicated topical gel containing PP405 0.05%, applied once daily to the scalp
Also known as: PP405 0.05%
Vehicle = placebo topical gel
Also known as: Topical Placebo
Percentage of Subjects With Adverse Events
An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase
Time frame: Baseline to Day 84 of the randomized portion of the study
Percentage of Subjects With Adverse Events
An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change in Local Dermal Tolerability as Assessed by Subject and Investigator
Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema
Time frame: Post-dose at day 28 of the randomized portion of the study
Change in Local Dermal Tolerability as Assessed by Subject and Investigator
Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema
Time frame: Post-dose at day 84 of the open label extension portion of the study
Change From Baseline in Blood Pressure
Change from baseline in blood pressure in the safety analysis population (day 84 minus baseline)
Time frame: Baseline to Day 84 of the randomized portion of the study
Change From Baseline in Pulse Rate
Change from baseline in pulse rate in the safety analysis population (day 84 minus baseline)
Time frame: Baseline to Day 84 of the randomized portion of the study
Change From Baseline in Temperature
Change from baseline in temperature in the safety analysis population (day 84 minus baseline)
Time frame: Baseline to Day 84 of the randomized portion of the study
Change From Baseline in Respiratory Rate
Change from baseline in respiratory rate in the safety analysis population (day 84 minus baseline)
Time frame: Baseline to Day 84 of the randomized portion of the study
Change From Baseline in Weight
Change from baseline in weight in the safety analysis population (day 84 minus baseline)
Time frame: Baseline to Day 84 of the randomized portion of the study
Change From Baseline in Blood Pressure
Change from baseline in blood pressure in the safety analysis population (open label extension day 84 minus open label extension baseline)
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change From Baseline in Pulse Rate
Change from baseline in pulse rate in the safety analysis population (open label extension day 84 minus open label extension baseline)
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change From Baseline in Temperature
Change from baseline in temperature in the safety analysis population (open label extension day 84 minus open label extension baseline)
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change From Baseline in Respiratory Rate
Change from baseline in respiratory rate in the safety analysis population (open label extension day 84 minus open label extension baseline)
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change From Baseline in Weight
Change from baseline in weight in the safety analysis population (open label extension day 84 minus open label extension baseline)
Time frame: Baseline to Day 84 of the open label extension portion of the study
Change From Baseline in Mean Electrocardiogram Heart Rate
Electrocardiogram mean heart rate was compared to baseline (day 28 minus baseline)
Time frame: Baseline to day 28 of the randomized portion of the study
Change From Baseline in Electrocardiogram (ECG) Results
Electrocardiograms results were compared to baseline (day 28 minus baseline)
Time frame: Baseline to day 28 of the randomized portion of the study
Change From Baseline in Mean Electrocardiogram Heart Rate
Mean Electrocardiogram Heart Rate was compared to baseline of the open label extension study (day 84 minus baseline)
Time frame: Baseline to day 84 of the open label extension portion of the study
Change From Baseline in Electrocardiograms (ECGs)
Electrocardiograms results were compared to baseline of the open label extension study (day 84 minus baseline)
Time frame: Baseline to day 84 of the open label extension portion of the study
Abnormal Laboratory Values
Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)
Time frame: Day 28 post baseline in the randomized portion of the study
Abnormal Laboratory Values
Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)
Time frame: Day 84 post baseline in the open label extension portion of the study
Pharmacokinetics of PP405
To assess the concentration of PP405 in plasma
Time frame: Baseline to Day 28 of the randomized portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 14, and day 28
Pharmacokinetics of PP405
To assess the concentration of PP405 in plasma
Time frame: Baseline to Day 84 of the open label extension portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 28, day 56, and day 84
| Milestone | PP405 0.05% Topical Gel Randomized Control Trial (28 Days of Treatment With Follow up to 84 Days) | Topical Vehicle Gel (Randomized), Then PP405 0.05% Topical Gel (Open Label Extension) |
|---|---|---|
| Started | 51 | 27 |
| Completed | 49 | 25 |
| Not completed | 2 | 2 |
| Milestone | PP405 0.05% Topical Gel Randomized Control Trial (28 Days of Treatment With Follow up to 84 Days) | Topical Vehicle Gel (Randomized), Then PP405 0.05% Topical Gel (Open Label Extension) |
|---|---|---|
| Started | 0 | 20 |
| Completed | 0 | 17 |
| Not completed | 0 | 3 |
An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase
| Participants | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| At least one adverse event | 22 | 10 |
| At least one treatment-emergent adverse event | 22 | 10 |
| At least one serious treatment-emergent adverse event | 0 | 1 |
An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase
| Participants | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| At least one adverse event | 8 |
| At least one treatment-emergent adverse event | 8 |
| At least one serious treatment-emergent adverse event | 0 |
Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema
| Participants | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Edema-investigator assessment — 0-None | 51 | 26 |
| Edema-investigator assessment — 1-Mild | 0 | 0 |
| Edema-investigator assessment — 2-Moderate | 0 | 0 |
| Edema-investigator assessment — 3-Severe | 0 | 0 |
| Erythema-investigator assessment — 0-None | 50 | 25 |
| Erythema-investigator assessment — 1-Mild | 1 | 1 |
| Erythema-investigator assessment — 2-Moderate | 0 | 0 |
| Erythema-investigator assessment — 3-Severe | 0 | 0 |
| Dryness-investigator assessment — 0-None | 51 | 26 |
| Dryness-investigator assessment — 1-Mild | 0 | 0 |
| Dryness-investigator assessment — 2-Moderate | 0 | 0 |
| Dryness-investigator assessment — 3-Severe | 0 | 0 |
| Scaling-investigator assessment — 0-None | 51 | 26 |
| Scaling-investigator assessment — 1-Mild | 0 | 0 |
| Scaling-investigator assessment — 2-Moderate | 0 | 0 |
| Scaling-investigator assessment — 3-Severe | 0 | 0 |
| Burning/stinging-subject assessment — 0-None | 51 | 25 |
| Burning/stinging-subject assessment — 1-Mild | 0 | 1 |
| Burning/stinging-subject assessment — 2-Moderate | 0 | 0 |
| Burning/stinging-subject assessment — 3-Severe | 0 | 0 |
| Pruritis-subject assessment — 0-None | 51 | 25 |
| Pruritis-subject assessment — 1-Mild | 0 | 1 |
| Pruritis-subject assessment — 2-Moderate | 0 | 0 |
| Pruritis-subject assessment — 3-Severe | 0 | 0 |
Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema
| Participants | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Edema-investigator assessment — 0-None | 16 |
| Edema-investigator assessment — 1-Mild | 0 |
| Edema-investigator assessment — 2-Moderate | 0 |
| Edema-investigator assessment — 3-Severe | 0 |
| Erythema-investigator assessment — 0-None | 15 |
| Erythema-investigator assessment — 1-Mild | 1 |
| Erythema-investigator assessment — 2-Moderate | 0 |
| Erythema-investigator assessment — 3-Severe | 0 |
| Dryness-investigator assessment — 0-None | 16 |
| Dryness-investigator assessment — 1-Mild | 0 |
| Dryness-investigator assessment — 2-Moderate | 0 |
| Dryness-investigator assessment — 3-Severe | 0 |
| Scaling-investigator assessment — 0-None | 16 |
| Scaling-investigator assessment — 1-Mild | 0 |
| Scaling-investigator assessment — 2-Moderate | 0 |
| Scaling-investigator assessment — 3-Severe | 0 |
| Burning/stinging-subject assessment — 0-None | 16 |
| Burning/stinging-subject assessment — 1-Mild | 0 |
| Burning/stinging-subject assessment — 2-Moderate | 0 |
| Burning/stinging-subject assessment — 3-Severe | 0 |
| Pruritis-subject assessment — 0-None | 16 |
| Pruritis-subject assessment — 1-Mild | 0 |
| Pruritis-subject assessment — 2-Moderate | 0 |
| Pruritis-subject assessment — 3-Severe | 0 |
Change from baseline in blood pressure in the safety analysis population (day 84 minus baseline)
| millimeters of mercury (mmHg) | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Systolic blood pressure | -0.6 ± 12.47 | -4.2 ± 12.02 |
| Diastolic blood pressure | 0.7 ± 10.17 | 1.1 ± 8.71 |
Change from baseline in pulse rate in the safety analysis population (day 84 minus baseline)
| beats per min | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Change From Baseline in Pulse Rate | 2.3 ± 9.89 | -2.3 ± 8.73 |
Change from baseline in temperature in the safety analysis population (day 84 minus baseline)
| degrees celcius | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Change From Baseline in Temperature | 0.110 ± 0.3084 | 0.000 ± 0.2931 |
Change from baseline in respiratory rate in the safety analysis population (day 84 minus baseline)
| breaths per minute | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Change From Baseline in Respiratory Rate | 0.0 ± 1.86 | -0.1 ± 1.38 |
Change from baseline in weight in the safety analysis population (day 84 minus baseline)
| kilograms | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Change From Baseline in Weight | 0.118 ± 1.9964 | 0.845 ± 2.1910 |
Change from baseline in blood pressure in the safety analysis population (open label extension day 84 minus open label extension baseline)
| millimeters of mercury (mmHg) | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Systolic blood pressure | -4.4 ± 10.91 |
| Diastolic blood pressure | -2.4 ± 5.91 |
Change from baseline in pulse rate in the safety analysis population (open label extension day 84 minus open label extension baseline)
| beats per minute | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Change From Baseline in Pulse Rate | 1.4 ± 8.36 |
Change from baseline in temperature in the safety analysis population (open label extension day 84 minus open label extension baseline)
| degrees celcius | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Change From Baseline in Temperature | 0.017 ± 0.2787 |
Change from baseline in respiratory rate in the safety analysis population (open label extension day 84 minus open label extension baseline)
| breaths per minute | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Change From Baseline in Respiratory Rate | 0.1 ± 0.85 |
Change from baseline in weight in the safety analysis population (open label extension day 84 minus open label extension baseline)
| kilograms | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Change From Baseline in Weight | -0.592 ± 3.2339 |
Electrocardiogram mean heart rate was compared to baseline (day 28 minus baseline)
| beats per minute | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Change From Baseline in Mean Electrocardiogram Heart Rate | 0.6 ± 9.97 | 1.8 ± 9.06 |
Electrocardiograms results were compared to baseline (day 28 minus baseline)
| milliseconds (ms) | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| PR Interval, Aggregate | 0.4 ± 11.87 | 3.8 ± 14.85 |
| QRS Duration, Aggregate | -0.6 ± 7.88 | 1.2 ± 5.57 |
| QT Interval, Aggregate | -0.9 ± 21.24 | -0.5 ± 21.90 |
| QTcB Interval, Aggregate | 1.3 ± 23.64 | 4.6 ± 20.41 |
| QTcF Interval, Aggregate | 0.5 ± 18.86 | 2.8 ± 17.58 |
| RR Interval, Aggregate | -9.7 ± 125.56 | -23.3 ± 123.29 |
Mean Electrocardiogram Heart Rate was compared to baseline of the open label extension study (day 84 minus baseline)
| beats per minute | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Change From Baseline in Mean Electrocardiogram Heart Rate | 0.7 ± 11.06 |
Electrocardiograms results were compared to baseline of the open label extension study (day 84 minus baseline)
| milliseconds (ms) | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| PR Interval, Aggregate | -1.3 ± 10.13 |
| QRS Duration, Aggregate | 0.2 ± 5.48 |
| QT Interval, Aggregate | -5.5 ± 20.96 |
| QTcB Interval, Aggregate | -2.7 ± 23.02 |
| QTcF Interval, Aggregate | -3.6 ± 16.15 |
| RR Interval, Aggregate | -17.3 ± 151.89 |
Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)
| Participants | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Albumin (g/L) — Low | 0 | 0 |
| Albumin (g/L) — Normal | 51 | 25 |
| Albumin (g/L) — High | 0 | 1 |
| Alkaline Phosphatase (IU/L) — Low | 0 | 0 |
| Alkaline Phosphatase (IU/L) — Normal | 51 | 24 |
| Alkaline Phosphatase (IU/L) — High | 0 | 2 |
| Alanine Aminotransferase (IU/L) — Low | 0 | 0 |
| Alanine Aminotransferase (IU/L) — Normal | 41 | 22 |
| Alanine Aminotransferase (IU/L) — High | 10 | 3 |
| Aspartate Aminotransferase (IU/L) — Low | 0 | 0 |
| Aspartate Aminotransferase (IU/L) — Normal | 45 | 25 |
| Aspartate Aminotransferase (IU/L) — High | 6 | 0 |
| Bicarbonate (mmol/L) — Low | 26 | 11 |
| Bicarbonate (mmol/L) — Normal | 25 | 15 |
| Bicarbonate (mmol/L) — High | 0 | 0 |
| Direct Bilirubin (umol/L) — Low | 0 | 0 |
| Direct Bilirubin (umol/L) — Normal | 50 | 25 |
| Direct Bilirubin (umol/L) — High | 1 | 0 |
| Bilirubin (umol/L) — Low | 0 | 0 |
| Bilirubin (umol/L) — Normal | 49 | 25 |
| Bilirubin (umol/L) — High | 2 | 0 |
| Calcium (mmol/L) — Low | 0 | 0 |
| Calcium (mmol/L) — Normal | 48 | 22 |
| Calcium (mmol/L) — High | 3 | 4 |
| Chloride (mmol/L) — Low | 1 | 0 |
| Chloride (mmol/L) — Normal | 50 | 26 |
| Chloride (mmol/L) — High | 0 | 0 |
| Cortisol (nmol/L) — Low | 0 | 0 |
| Cortisol (nmol/L) — Normal | 49 | 25 |
| Cortisol (nmol/L) — High | 2 | 1 |
| Creatinine (umol/L) — Low | 1 | 2 |
| Creatinine (umol/L) — Normal | 47 | 24 |
| Creatinine (umol/L) — High | 3 | 0 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Low | 0 | 0 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Normal | 51 | 26 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — High | 0 | 0 |
| Gamma Glutamyl Transferase (IU/L) — Low | 0 | 0 |
| Gamma Glutamyl Transferase (IU/L) — Normal | 47 | 26 |
| Gamma Glutamyl Transferase (IU/L) — High | 4 | 0 |
| Glucose (mmol/L) — Low | 0 | 0 |
| Glucose (mmol/L) — Normal | 49 | 25 |
| Glucose (mmol/L) — High | 2 | 1 |
| Prothrombin Intl. Normalized Ratio — Low | 0 | 0 |
| Prothrombin Intl. Normalized Ratio — Normal | 45 | 19 |
| Prothrombin Intl. Normalized Ratio — High | 4 | 7 |
| Potassium (mmol/L) — Low | 1 | 0 |
| Potassium (mmol/L) — Normal | 49 | 26 |
| Potassium (mmol/L) — High | 1 | 0 |
| Lactate Dehydrogenase (IU/L) — Low | 7 | 4 |
| Lactate Dehydrogenase (IU/L) — Normal | 42 | 22 |
| Lactate Dehydrogenase (IU/L) — High | 2 | 0 |
| Phosphate (mmol/L) — Low | 3 | 1 |
| Phosphate (mmol/L) — Normal | 46 | 23 |
| Phosphate (mmol/L) — High | 2 | 1 |
| Protein (g/L) — Low | 4 | 0 |
| Protein (g/L) — Normal | 47 | 26 |
| Protein (g/L) — High | 0 | 0 |
| Sodium (mmol/L) — Low | 0 | 0 |
| Sodium (mmol/L) — Normal | 51 | 25 |
| Sodium (mmol/L) — High | 0 | 1 |
| Urate (umol/L) — Low | 0 | 0 |
| Urate (umol/L) — Normal | 43 | 23 |
| Urate (umol/L) — High | 8 | 3 |
| Urea Nitrogen (mmol/L) — Low | 3 | 2 |
| Urea Nitrogen (mmol/L) — Normal | 46 | 24 |
| Urea Nitrogen (mmol/L) — High | 2 | 0 |
| Basophils (10^9/L) — Low | 0 | 0 |
| Basophils (10^9/L) — Normal | 51 | 26 |
| Basophils (10^9/L) — High | 0 | 0 |
| Basophils/Leukocytes (%) — Low | 0 | 0 |
| Basophils/Leukocytes (%) — Normal | 48 | 24 |
| Basophils/Leukocytes (%) — High | 3 | 2 |
| Eosinophils (10^9/L) — Low | 0 | 0 |
| Eosinophils (10^9/L) — Normal | 51 | 26 |
| Eosinophils (10^9/L) — High | 0 | 0 |
| Eosinophils/Leukocytes (%) — Low | 0 | 0 |
| Eosinophils/Leukocytes (%) — Normal | 51 | 24 |
| Eosinophils/Leukocytes (%) — High | 0 | 2 |
| Hematocrit (L/L) — Low | 0 | 0 |
| Hematocrit (L/L) — Normal | 50 | 25 |
| Hematocrit (L/L) — High | 1 | 1 |
| Hemoglobin (g/L) — Low | 4 | 0 |
| Hemoglobin (g/L) — Normal | 45 | 25 |
| Hemoglobin (g/L) — High | 2 | 1 |
| Lymphocytes (10^9/L) — Low | 7 | 1 |
| Lymphocytes (10^9/L) — Normal | 42 | 25 |
| Lymphocytes (10^9/L) — High | 2 | 0 |
| Lymphocytes/Leukocytes (%) — Low | 2 | 1 |
| Lymphocytes/Leukocytes (%) — Normal | 49 | 23 |
| Lymphocytes/Leukocytes (%) — High | 0 | 2 |
| Ery. Mean Corpuscular Hemoglobin (pg) — Low | 2 | 0 |
| Ery. Mean Corpuscular Hemoglobin (pg) — Normal | 45 | 25 |
| Ery. Mean Corpuscular Hemoglobin (pg) — High | 4 | 1 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — Low | 37 | 17 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — Normal | 14 | 9 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — High | 0 | 0 |
| Ery. Mean Corpuscular Volume (fL) — Low | 0 | 0 |
| Ery. Mean Corpuscular Volume (fL) — Normal | 26 | 12 |
| Ery. Mean Corpuscular Volume (fL) — High | 25 | 14 |
| Monocytes (10^9/L) — Low | 3 | 1 |
| Monocytes (10^9/L) — Normal | 48 | 25 |
| Monocytes (10^9/L) — High | 0 | 0 |
| Monocytes/Leukocytes (%) — Low | 2 | 0 |
| Monocytes/Leukocytes (%) — Normal | 49 | 26 |
| Monocytes/Leukocytes (%) — High | 0 | 0 |
| Neutrophils (10^9/L) — Low | 2 | 2 |
| Neutrophils (10^9/L) — Normal | 47 | 24 |
| Neutrophils (10^9/L) — High | 2 | 0 |
| Neutrophils/Leukocytes (%) — Low | 1 | 2 |
| Neutrophils/Leukocytes (%) — Normal | 48 | 23 |
| Neutrophils/Leukocytes (%) — High | 2 | 1 |
| Platelets (10^9/L) — Low | 2 | 0 |
| Platelets (10^9/L) — Normal | 43 | 24 |
| Platelets (10^9/L) — High | 6 | 2 |
| Erythrocytes (10^12/L) — Low | 4 | 0 |
| Erythrocytes (10^12/L) — Normal | 43 | 26 |
| Erythrocytes (10^12/L) — High | 4 | 0 |
| Leukocytes (10^9/L) — Low | 3 | 0 |
| Leukocytes (10^9/L) — Normal | 46 | 26 |
| Leukocytes (10^9/L) — High | 2 | 0 |
Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)
| Participants | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Albumin (g/L) — Low | 0 |
| Albumin (g/L) — Normal | 20 |
| Albumin (g/L) — High | 0 |
| Alkaline Phosphatase (IU/L) — Low | 0 |
| Alkaline Phosphatase (IU/L) — Normal | 19 |
| Alkaline Phosphatase (IU/L) — High | 1 |
| Alanine Aminotransferase (IU/L) — Low | 0 |
| Alanine Aminotransferase (IU/L) — Normal | 18 |
| Alanine Aminotransferase (IU/L) — High | 2 |
| Aspartate Aminotransferase (IU/L) — Low | 0 |
| Aspartate Aminotransferase (IU/L) — Normal | 19 |
| Aspartate Aminotransferase (IU/L) — High | 1 |
| Bicarbonate (mmol/L) — Low | 14 |
| Bicarbonate (mmol/L) — Normal | 6 |
| Bicarbonate (mmol/L) — High | 0 |
| Direct Bilirubin (umol/L) — Low | 0 |
| Direct Bilirubin (umol/L) — Normal | 18 |
| Direct Bilirubin (umol/L) — High | 2 |
| Bilirubin (umol/L) — Low | 0 |
| Bilirubin (umol/L) — Normal | 19 |
| Bilirubin (umol/L) — High | 1 |
| Calcium (mmol/L) — Low | 0 |
| Calcium (mmol/L) — Normal | 20 |
| Calcium (mmol/L) — High | 0 |
| Chloride (mmol/L) — Low | 0 |
| Chloride (mmol/L) — Normal | 19 |
| Chloride (mmol/L) — High | 1 |
| Cortisol (nmol/L) — Low | 0 |
| Cortisol (nmol/L) — Normal | 20 |
| Cortisol (nmol/L) — High | 0 |
| Creatinine (umol/L) — Low | 0 |
| Creatinine (umol/L) — Normal | 19 |
| Creatinine (umol/L) — High | 1 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Low | 0 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Normal | 20 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — High | 0 |
| Gamma Glutamyl Transferase (IU/L) — Low | 1 |
| Gamma Glutamyl Transferase (IU/L) — Normal | 18 |
| Gamma Glutamyl Transferase (IU/L) — High | 1 |
| Glucose (mmol/L) — Low | 0 |
| Glucose (mmol/L) — Normal | 18 |
| Glucose (mmol/L) — High | 2 |
| Prothrombin Intl. Normalized Ratio — Low | 0 |
| Prothrombin Intl. Normalized Ratio — Normal | 16 |
| Prothrombin Intl. Normalized Ratio — High | 4 |
| Potassium (mmol/L) — Low | 0 |
| Potassium (mmol/L) — Normal | 20 |
| Potassium (mmol/L) — High | 0 |
| Lactate Dehydrogenase (IU/L) — Low | 4 |
| Lactate Dehydrogenase (IU/L) — Normal | 16 |
| Lactate Dehydrogenase (IU/L) — High | 0 |
| Phosphate (mmol/L) — Low | 0 |
| Phosphate (mmol/L) — Normal | 20 |
| Phosphate (mmol/L) — High | 0 |
| Protein (g/L) — Low | 1 |
| Protein (g/L) — Normal | 19 |
| Protein (g/L) — High | 0 |
| Sodium (mmol/L) — Low | 0 |
| Sodium (mmol/L) — Normal | 20 |
| Sodium (mmol/L) — High | 0 |
| Urate (umol/L) — Low | 0 |
| Urate (umol/L) — Normal | 19 |
| Urate (umol/L) — High | 1 |
| Urea Nitrogen (mmol/L) — Low | 2 |
| Urea Nitrogen (mmol/L) — Normal | 17 |
| Urea Nitrogen (mmol/L) — High | 1 |
| Basophils (10^9/L) — Low | 0 |
| Basophils (10^9/L) — Normal | 20 |
| Basophils (10^9/L) — High | 0 |
| Basophils/Leukocytes (%) — Low | 0 |
| Basophils/Leukocytes (%) — Normal | 19 |
| Basophils/Leukocytes (%) — High | 1 |
| Eosinophils (10^9/L) — Low | 0 |
| Eosinophils (10^9/L) — Normal | 20 |
| Eosinophils (10^9/L) — High | 0 |
| Eosinophils/Leukocytes (%) — Low | 0 |
| Eosinophils/Leukocytes (%) — Normal | 20 |
| Eosinophils/Leukocytes (%) — High | 0 |
| Hematocrit (L/L) — Low | 0 |
| Hematocrit (L/L) — Normal | 20 |
| Hematocrit (L/L) — High | 0 |
| Hemoglobin (g/L) — Low | 2 |
| Hemoglobin (g/L) — Normal | 17 |
| Hemoglobin (g/L) — High | 1 |
| Lymphocytes (10^9/L) — Low | 2 |
| Lymphocytes (10^9/L) — Normal | 18 |
| Lymphocytes (10^9/L) — High | 0 |
| Lymphocytes/Leukocytes (%) — Low | 1 |
| Lymphocytes/Leukocytes (%) — Normal | 19 |
| Lymphocytes/Leukocytes (%) — High | 0 |
| Ery. Mean Corpuscular Hemoglobin (pg) — Low | 0 |
| Ery. Mean Corpuscular Hemoglobin (pg) — Normal | 20 |
| Ery. Mean Corpuscular Hemoglobin (pg) — High | 0 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — Low | 15 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — Normal | 5 |
| Ery. Mean Corpuscular HGB Concentration (g/L) — High | 0 |
| Ery. Mean Corpuscular Volume (fL) — Low | 0 |
| Ery. Mean Corpuscular Volume (fL) — Normal | 11 |
| Ery. Mean Corpuscular Volume (fL) — High | 9 |
| Monocytes (10^9/L) — Low | 0 |
| Monocytes (10^9/L) — Normal | 20 |
| Monocytes (10^9/L) — High | 0 |
| Monocytes/Leukocytes (%) — Low | 0 |
| Monocytes/Leukocytes (%) — Normal | 20 |
| Monocytes/Leukocytes (%) — High | 0 |
| Neutrophils (10^9/L) — Low | 0 |
| Neutrophils (10^9/L) — Normal | 20 |
| Neutrophils (10^9/L) — High | 0 |
| Neutrophils/Leukocytes (%) — Low | 1 |
| Neutrophils/Leukocytes (%) — Normal | 18 |
| Neutrophils/Leukocytes (%) — High | 1 |
| Platelets (10^9/L) — Low | 0 |
| Platelets (10^9/L) — Normal | 19 |
| Platelets (10^9/L) — High | 1 |
| Erythrocytes (10^12/L) — Low | 0 |
| Erythrocytes (10^12/L) — Normal | 19 |
| Erythrocytes (10^12/L) — High | 1 |
| Leukocytes (10^9/L) — Low | 0 |
| Leukocytes (10^9/L) — Normal | 20 |
| Leukocytes (10^9/L) — High | 0 |
To assess the concentration of PP405 in plasma
| nanograms per milliliter (ng/mL) | PP405 0.05% Topical Gel (Randomized Controlled Trial Period) | Vehicle Gel (Randomized Controlled Trial Period) |
|---|---|---|
| Day 1 | 0 (0 to 0) | — |
| Day 14 | 0 (0 to 0) | — |
| Day 28 | 0 (0 to 0) | — |
To assess the concentration of PP405 in plasma
| nanograms per milliliter (ng/mL) | PP405 0.05% Topical Gel (Open Label Extension Period) |
|---|---|
| Day 1 | 0 (0 to 0) |
| Day 28 | 0 (0 to 0) |
| Day 56 | 0 (0 to 0) |
| Day 84 | 0 (0 to 0) |
Collected over Day 1 through day 84 of the randomized controlled portion of the study, and day 1 through day 168 of the open label extension portion of the study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PP405 0.05% Topical Gel (Randomized Controlled Trial) | 0/51 (0%) | 0/51 (0%) | 22/51 (43.1%) |
| Topical Vehicle Gel (Randomized Controlled Trial) | 0/27 (0%) | 1/27 (3.7%) | 10/27 (37%) |
| PP405 0.05% Topical Gel (Open Label Extension) | 0/20 (0%) | 0/20 (0%) | 8/20 (40%) |
| Event | PP405 0.05% Topical Gel (Randomized Controlled Trial) | Topical Vehicle Gel (Randomized Controlled Trial) | PP405 0.05% Topical Gel (Open Label Extension) |
|---|---|---|---|
| Upper extremity fractureInjury, poisoning and procedural complications | 0/51 | 1/27 | — |
| Event | PP405 0.05% Topical Gel (Randomized Controlled Trial) | Topical Vehicle Gel (Randomized Controlled Trial) | PP405 0.05% Topical Gel (Open Label Extension) |
|---|---|---|---|
| Application site erythemaGeneral disorders | 4/51 | 3/27 | 3/20 |
| Application site pruritisGeneral disorders | 7/51 | 2/27 | 2/20 |
| PruritisSkin and subcutaneous tissue disorders | 3/51 | 3/27 | 1/20 |
| Application site exfoliationGeneral disorders | 0/51 | 1/27 | 2/20 |
| Application site painGeneral disorders | 2/51 | 2/27 | 0/20 |
| COVID-19Infections and infestations | 2/51 | 0/27 | 1/20 |
| Alanine aminotransferase increasedInvestigations | 0/51 | 0/27 | 1/20 |
| Ligament sprainInjury, poisoning and procedural complications | 0/51 | 0/27 | 1/20 |
| Fungal infectionInfections and infestations | 0/51 | 0/27 | 1/20 |
| Viral upper respiratory tract infectionInfections and infestations | 0/51 | 0/27 | 1/20 |
| Age, Continuous(years) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Mean | 39.0 ± 8.08 | 38.4 ± 9.38 | 38.8 ± 8.50 |
| Sex: Female, Male(Participants) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 45 | 23 | 68 |
| Ethnicity (NIH/OMB)(Participants) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 5 | 19 |
| Not Hispanic or Latino | 37 | 22 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 3 | 11 |
| White | 35 | 21 | 56 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| United States | 51 | 27 | 78 |
| Height(Centimeters) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Mean | 174.09 ± 8.989 | 176.13 ± 8.850 | 174.80 ± 8.936 |
| Weight(kilograms) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Mean | 88.71 ± 18.221 | 87.05 ± 84.37 | 88.14 ± 17.934 |
| Body mass index(kilograms / (meters^2)) | PP405 0.05% Topical Gel | Topical Vehicle Gel, Then PP405 0.05% Topical Gel | Total |
|---|---|---|---|
| Mean | 29.20 ± 5.182 | 28.03 ± 5.286 | 28.80 ± 5.214 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Jul 2025, 13 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JXL-069
Pelage Pharmaceuticals, Inc.